Establish herd effect to interrupt wild poliovirus transmission by Jacob John, T.
Editorial
Indian J Med Res 124, July 2006, pp 1-4
Wild-virus polio cases in India in the first six
months of 2006 (n = 70) have exceeded those during
all of 2005 (n = 66) (http://www.npsindia.org).
Transmission persists in western Uttar Pradesh (UP)
with rising numbers and in Bihar with declining
numbers. India and 3 other countries - Pakistan,
Afghanistan and Nigeria, have failed to interrupt wild
virus transmission in 2006. India was a leader in
research on poliovirus epidemiology and vaccinology
in 1970s and 1980s. Instead of assuming leadership
in their application, India slipped to failure, only
because science was ignored in public health policy.
One could defend that 2006 is an ‘outbreak’
year, as were 2002 and 1998 previously, at 4-year
intervals. That is no consolation, as all subsequent
efforts could not avert an outbreak. A call was made,
in vain, for an exclusive internal Indian review of
the scientific basis of the polio eradication
interventions1. The force of transmission of wild
polioviruses varies in populations and western UP
may have one of the highest2,3. Vaccine efficacy of
OPV also varies and it may be the lowest in western
UP3. Among the many OPV response studies, one of
the lowest recorded results in the world was in Delhi,
close to the border of western UP4. A coincidence of
these two adverse phenomena may explain the
persistence of transmission3. India needs a way
forward, based on tactics built upon scientific
rationale and evidence.
Elimination of wild virus transmission is clearly
impossible in 2006. Time over-run beyond the target
year of 2000 has caused cost over-run. Globally over
4 billion dollars have been spent, while the original
budget was only half as much. India had been
spending more than what the country can afford,
while other health programmes are being adversely
affected.  If India does not succeed by 2007, when
wild poliovirus (along with new subtypes of
influenza, SARS and smallpox) will become
notifiable under the new ‘International Health
Regulations 2005,’ the consequence could be
embarrassing5. The delay has its local repercussions
as well. According to rumour, health workers are
losing faith in OPV as had many families in the past,
as polio occurs in children despite taking 10 or more
doses. Consequently the quality of immunization
campaigns may deteriorate. If this state of affairs
continues, improved intervention may not be
implemented well. The longer the delay, the greater
is the risk of losing much of the gains achieved so
far.  Any slip-up in immunization pressure may result
in wild virus re-infection in other States and
exportation to other countries. Urgent steps to design
and deploy effective tactics to eliminate wild viruses
in the shortest time are the immediate priority.
The elimination of a pathogen by immunization
requires two elements - ‘vaccine delivery’ and
‘vaccine effectiveness’. Unfortunately these were not
optimized synchronously - when the programme
improved on delivery, the inadequacy of vaccine
effectiveness was not corrected. In recent years the
pace of supplementary vaccination activities was
more intense here than most, if not all, other places
in the world. Western UP had 6 rounds of OPV
campaign in 2003, 6 in 2004 and 8 in 2005. The
quality of campaigns has been under close scrutiny
and the coverage has been well in excess of 90 per
cent each time. The average number of OPV given
to under-5 children is 15. Other countries and other
Indian States eliminated wild virus transmission with
far less intense efforts2. The Government of India
(GoI) and the National Polio Surveillance Project
have so far spared no effort in their respective
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managerial roles. The implementation partners,
particularly the State Governments, UNICEF, Rotary
International, the core group of non government
organizations (NGOs), Indian Academy of Pediatrics
and others have worked really hard; yet success has
eluded them. Vaccine delivery of OPV has been
excellent, if we ignore the low ‘routine’ vaccination
rates.
The deficiency of vaccine effectiveness had been
staring at us for years, but only now have most
stakeholders noticed it. Delivered doses were not
providing protective immunity to a substantial
proportion of children2,3. The effectiveness of a
vaccine for disease control requires vaccine efficacy
(VE) and herd effect (HE). Vaccination is primarily
to prevent disease in the vaccinated individual when
exposed to the pathogen. The probability of
protection (immunity) is measured in a group of
individuals and is expressed as vaccine efficacy. The
protected individual may still get infected when
exposed, but infection does not progress to disease;
thus it is modified to a varying degree. Lack of
protection in spite of vaccination is vaccine failure,
the frequency of which is inversely proportional to
VE. The modified infection in immunized individual
has an effect on the quantum, duration or both, of
pathogen-shedding, the essential link in the chain of
transmission to new hosts. Even slight reduction of
shedding (quantum or duration) decreases
transmission efficiency.  The more the proportion of
subjects vaccinated, and the longer the vaccination
pressure is sustained, the greater the reduction of
transmission efficiency. This is the basis of HE,
defined as the decline in incidence of disease (and
infection) in the unvaccinated segment of a
population in which a proportion is vaccinated6. The
greater the fall in transmission efficiency, the slower
will be the spread of infection and lesser the number
newly infected. The slowing speed of spread is
evidenced by rising median age by which 50 per cent
of cases had occurred. As disease frequency is
directly proportional to that of infection (in the non-
immune), this upward age shift is the visible evidence
of slowing transmission.  The falling number of new
infections is evidenced by declining incidence of
disease among the unvaccinated. If these trends are
sustained by sustained immunization pressure, there
will be a cascading effect, resulting in downward
spiral of falling incidence of infection - consequently,
first disease incidence and eventually infection
incidence will reach zero, and infection is eliminated
from the community. Unless re-introduced from
outside, infection cannot reappear.
The two factors for obtaining high HE are high
VE and high vaccine coverage. The former is an
attribute of the vaccine and the latter depends on the
quality of the vaccination programme. It is therefore
important to assess the VE, vaccine coverage and HE,
in the districts where transmission has not been
interrupted. The two signals of HE are an upward
shift of the age of children with polio and a fall in
incidence that is disproportionately greater than the
vaccination coverage. What we see in western UP
are the lack of upward age shift and slower fall of
incidence than vaccination coverage. Well over two-
thirds of cases continue to occur below 24 months of
age, as had always been in the past. The median age
continues around 12-18 months. As virtually 100 per
cent are vaccinated with multiple doses of OPV, the
fall in incidence is lesser than coverage. Both these
signals point to a lack of HE. Since coverage is almost
at saturation level, VE is clearly deficient.
All vaccines against anthroponoses (human-to-
human transmitted infectious diseases) that protect
against the infectious form of disease exhibit HE.
Thus, diphtheria toxoid, whole cell or acellular
pertussis vaccine, killed influenza, hepatitis A and
poliovirus vaccines, capsular polysaccharide
Haemophilus influenzae  b and pneumococcal
vaccines, live virus vaccines against polio, measles,
etc., have all been shown to exhibit HE in different
parts of the world. The one exception, namely BCG,
does not protect against the infectious form of
tuberculosis and has no HE. Among all others OPV
alone has wide variations of VE (hence HE also) in
different geographic settings. They are very low in
India7-9.
Among the virus types in trivalent OPV, type 2
is more immunogenic with higher VE than others4,7.
Type 2 transmission ceased in western UP in October
1999. This provides the clue that coverage using
trivalent OPV was indeed high enough to eliminate
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that pathogen against which VE was high. Western
UP was the very last place on earth to interrupt its
transmission highlighting the problems of this
geographic population. In UP (and Bihar to a lesser
degree) the VE of types 1 and 3 is unacceptably low.
Even with near 100 per cent coverage trivalent OPV
does not show sufficient or even detectable HE
against them. This interpretation is critical for re-
designing future interventions. The median age of
polio remains at the 12-18 months level; nearly half
the cases are in 10-dose-recipients; nearly all cases
had taken at least 4 doses of OPV. These observations
tell us two things. First, it will take more than 10
doses to immunize all infants against types 1 and 3.
Second, the speed of wild virus transmission is faster
than the speed with which children are being
immunized. Unless infants are fully immunized by
age 6-9 months, it seems unlikely that this vicious
cycle will be broken. This translates to at least 10
doses of OPV given to infants by 6-9 months of age.
Unfortunately this speed is not practical, since every
month from birth every infant will have to be
contacted. If monovalent types 1 and 3 OPV were to
be used, the VE per dose will improve, and probably
the number of doses needed may be somewhat less.
This approach requires scientific validation by
specific studies, but we do not have the luxury of
time in our favour. As an aside, there is no scientific
reason to continue giving type 2 vaccine to children.
Since bivalent vaccine with types 1 and 3 is not
licensed anywhere, the logical option is to use only
types 1 and 3 monovalent OPV in a suitable
sequential manner. The hidden advantage to this
approach is a natural experiment, to document the
probability of emergence of circulating vaccine-
derived poliovirus (cVDPV) type 2, after that vaccine
is discontinued.
The safer alternative for faster result is to
vaccinate with 3 doses of IPV, which will provide
better immunity than even 10 doses of OPV, in terms
of higher proportion (virtually 100%) of infants
developing immune response as well as achieving
markedly higher antibody titres7. Thus, the addition
of IPV appears to be the most promising way forward
to interrupt wild virus transmission in the shortest
possible time. This method need not drastically affect
OPV delivery, either routine or in campaigns.
Therefore it can be implemented without further
studies, although the new tactic itself must be
monitored for coverage and efficacy.
There are additional advantages to this approach.
First, IPV protects against vaccine-induced polio
(called VAPP i.e., vaccine-associated paralytic
polio). Currently 150-200 children get VAPP
annually in India10. During the past decade 1500-2000
children were paralysed, but not recognized or
compensated. There is no ethical justification to
cause more disease due to the intervention, than the
disease intervened against. Minimum ethical
requirement is free treatment and rehabilitation of
all children directly affected by the intervention
meant for the benefit of the majority. To prevent
VAPP is clearly an ethical necessity. Eventually India
must discontinue OPV and the build-up of an IPV
programme will help the transition to be risk-free
from cVDPV3. By commencing an IPV programme
now we will shorten the transition to the final phase
of eradication, when OPV will no longer be in use3.
What is the scientific evidence that IPV has HE?
In many geographic settings it is highly immunogenic
and has very high VE.  Infants can be fully
immunized by the age of 4-6 months, before they
amplify and disseminate wild viruses in the
community. Experience in USA and Europe has
shown excellent HE8. Very few studies have been
conducted in India on the immunogenicity and HE
of IPV, but each of them had shown high
immunogenicity or remarkable HE8,9. Based on such
evidence, one private company manufactured DPT-
combined IPV in 1986-87 but had to stop as directed
by the GoI. In 1987, the GoI itself embarked on a
mission to manufacture IPV in the public sector, to
expedite polio control using both OPV and IPV and
to gain experience with the latter. Concurrently a
pilot project was approved in the North Arcot district
in Tamil Nadu, to examine the potential of IPV in
controlling polio and the results were highly
encouraging. In 1988, the GoI committed itself on
eradication by 2000 in the World Health Assembly
(WHA), but gradually retreated from the ‘open-
minded’ position on vaccines, to the exclusive use
of OPV, against advice from scientists inside the
country. The National Regulatory Authority declined
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to license IPV in India and eventually the public
sector IPV plant was also closed down. These
strongly suggest an unscientific bias in favour of
OPV and prejudice against IPV. Thus, India forced
itself to use OPV exclusively for eradication,
knowing fully well the possibility of failure. No pilot
studies were conducted.
Pulse vaccination was shown to improve VE of
OPV9. It called for 3 doses at monthly intervals,
giving the health system the remaining 9 months of
the year to improve the ‘routine’ immunization.
Within 2-3 yr wild-virus transmission would have
stopped in the easy States, but others would have
failed. By examining the vaccination status and age
of children with polio in the problem areas, the cause
would have become clear - was it due to failure to
vaccinate (inadequate coverage) or failure of vaccine
(inadequate VE and HE)? The programme
implementers did not think through these critical
questions, but concentrated on the ‘failure to
vaccinate’ theory and ensured very high, indeed one
of the world’s highest, vaccine coverage levels with
multiple doses of OPV. Ignoring the ‘failure of
vaccine’ side of the equation haunts the programme
now. The lack of research in this enormously
expensive and ambitious programme has resulted in
the lack of timely grasp of the peculiar problem of
very low VE and HE of OPV where they are most
needed.
The lack of research on IPV, other than one
successful study in Tamil Nadu, and the reluctance
to take follow up action on its findings are further
pointers to an unscientific outlook towards
poliovaccines. One cannot revise the past, but can
re-design the future. But, when the tactics are
adjusted in future, to obtain high VE by using 3 doses
of IPV or multiple doses of OPV (trivalent or better
monovalent) by 6-9 months of age, or a suitable
combination of both vaccines in sufficient number
of doses, will the vaccine delivery arm of the
programme remain robust and maintain the tempo
to achieve high coverage? This is what the GoI must
now ensure, while new tactics are designed and
deployed.
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